Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Frontage Laboratories

Explore full profile

Pharmaceutical contract research organization

Upper Merion Township, United StatesFounded 2001Biotech & Life Sciences
Valuation $50–100M Last recorded · 2014
Headcount 500–1k Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Frontage Laboratories and the history behind them.

About Frontage Laboratories

Frontage Laboratories operates as a contract research organization (CRO), providing integrated services for the pharmaceutical and biotechnology industries. The company was founded in 2001 by Dr. Song Li, who established the firm with an initial investment of approximately $100,000 in New Jersey. Dr. Li, who holds a Ph.D. in Analytical Chemistry from McGill University, brought prior experience from management roles at Great Valley Pharmaceuticals and Wyeth, where he led various pharmaceutical product development projects. The company relocated its headquarters to Exton, Pennsylvania, in 2004 and has since expanded its operations globally, with 26 facilities across North America and China.

The business functions as a service-based entity, generating revenue by offering a comprehensive suite of solutions that support the entire drug development lifecycle, from initial discovery to late-phase clinical trials. Its clients range from emerging biotechnology startups to large pharmaceutical corporations. Frontage’s service model is designed as a “one-stop-shop,” which allows clients to outsource complex development processes, thereby leveraging the CRO’s operational efficiencies and scientific expertise. The company has positioned itself with a “Two Continents, One System” approach, ensuring consistent quality standards across its operations in the United States and China, the two largest markets for CRO services.

Frontage provides an extensive portfolio of services. These include drug discovery, preclinical services such as safety and toxicology assessment, and Drug Metabolism and Pharmacokinetics (DMPK). The company also offers Chemistry, Manufacturing, and Controls (CMC) services, which encompass formulation development, analytical testing, and GMP manufacturing of clinical trial materials for various dosage forms like oral solids, injectables, and topicals. In the clinical phase, Frontage supports Phase I-IIa studies with bioanalysis, biomarker research, and biometrics services, including data management and statistical programming. This integrated model enables the company to assist clients in advancing molecules through the development process and preparing regulatory submissions such as IND, NDA, and ANDA for global markets.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2001
Headquarters
Upper Merion Township, United States
Employees
700
Open positions
9
Dealroom signal
45.6/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Testing, Biotechnology, Drug Development, Biotech and Pharma, Hard Tech, medical testing, DT and LS, science-based
Client focus
b2b
Investment activity
6 companies, latest Mar 2026
Capital deployed
—
Preferred round
ACQUISITION

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCEquity / VC Mar 2018 $32M $130M Undisclosed —
ACQUISITION✓Exit May 2014 $50M $50M Undisclosed —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Frontage Laboratories website traffic

Latest recorded traffic for Frontage Laboratories is 22K monthly website visits, up 147.2% over the last three months. Frontage Laboratories's team grew 52.2% over the past year.

Latest monthly visits22K 3-month web change+147.2% 1-year team growth+52.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • Robert W. Baird & Co.

Other known investors1 additional known investor

  • Baird Capital
Team profiled 14 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
6 countries with
team presence
🇺🇸 United States90.5%
🇨🇳 China5.1%
🇮🇹 Italy2.3%
🇨🇦 Canada1.2%
🇭🇰 Hong Kong0.4%
Top 5 of 6 shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Frontage Laboratories on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Frontage Laboratories’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.